Cocrystal Pharma (COCP) Non-Current Deferred Tax Liability (2010 - 2020)

Cocrystal Pharma (COCP) has 11 years of Non-Current Deferred Tax Liability data on file, last reported at $2.2 million in Q4 2020.

• For the quarter ending Q4 2020, Non-Current Deferred Tax Liability rose 24144.44% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2020 stood at $2.2 million (up 24144.44% YoY), and the FY2020 full-year result was $2.2 million, up 24144.44% from the prior year.
• Non-Current Deferred Tax Liability improved to $2.2 million in Q4 2020, from $9000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $49.9 million in Q1 2016 to a low of $9000.0 in Q4 2019.
• A 5-year average of $18.3 million and a median of $12.9 million in 2018 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability sank 99.56% in 2019 and jumped 24144.44% in 2020, its largest moves.
• Tracing COCP's Non-Current Deferred Tax Liability over 5 years: stood at $1.4 million in 2016, then advanced by 28.71% to $1.8 million in 2017, then climbed by 13.08% to $2.0 million in 2018, then tumbled by 99.56% to $9000.0 in 2019, then jumped by 24144.44% to $2.2 million in 2020.
• Business Quant data shows COCP's Non-Current Deferred Tax Liability at $2.2 million in Q4 2020, $9000.0 in Q4 2019, and $2.0 million in Q4 2018.